• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.

作者信息

Christensen B, Sparrow M P

机构信息

Department of Gastroenterology, Alfred Hospital and Monash University, Melbourne, Vic., Australia.

出版信息

Aliment Pharmacol Ther. 2017 Jan;45(1):178-179. doi: 10.1111/apt.13842.

DOI:10.1111/apt.13842
PMID:27910149
Abstract
摘要

相似文献

1
Editorial: adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.
Aliment Pharmacol Ther. 2017 Jan;45(1):178-179. doi: 10.1111/apt.13842.
2
Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study.英夫利昔单抗与阿达木单抗治疗克罗恩病的比较：澳大利亚和新西兰一项观察性队列研究中327例患者的结果
Aliment Pharmacol Ther. 2017 Feb;45(4):542-552. doi: 10.1111/apt.13880. Epub 2016 Dec 19.
3
Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.抗 TNF 单药治疗克罗恩病：13 年多中心经验
J Crohns Colitis. 2016 May;10(5):516-24. doi: 10.1093/ecco-jcc/jjw008. Epub 2016 Jan 22.
4
Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.阿达木单抗或英夫利昔单抗单药治疗，或与免疫调节剂联合治疗，用于治疗克罗恩病。
Aliment Pharmacol Ther. 2016 Nov;44(10):1102-1113. doi: 10.1111/apt.13808. Epub 2016 Sep 26.
5
Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis.阿达木单抗单药治疗与免疫调节剂联合治疗克罗恩病患者的系统评价和荟萃分析
J Crohns Colitis. 2014 Dec;8(12):1632-41. doi: 10.1016/j.crohns.2014.07.003. Epub 2014 Jul 25.
6
Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort.
Aliment Pharmacol Ther. 2017 Mar;45(6):855-856. doi: 10.1111/apt.13929.
7
Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort - authors' reply.
Aliment Pharmacol Ther. 2017 Mar;45(6):856-857. doi: 10.1111/apt.13968.
8
Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.用于维持克罗恩病缓解的肿瘤坏死因子-α抗体。
Cochrane Database Syst Rev. 2008 Jan 23(1):CD006893. doi: 10.1002/14651858.CD006893.
9
Autoimmune hepatitis induced by infliximab in a patient with Crohn's disease with no relapse after switching to adalimumab.英夫利昔单抗诱导克罗恩病患者发生自身免疫性肝炎，转换用阿达木单抗后无复发。
BioDrugs. 2010 Dec 14;24 Suppl 1:25-7. doi: 10.2165/11586210-000000000-00000.
10
Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.早期使用抗肿瘤坏死因子-α与免疫调节剂治疗儿童克罗恩病的效果增加。
Gastroenterology. 2014 Feb;146(2):383-91. doi: 10.1053/j.gastro.2013.10.027. Epub 2013 Oct 23.